Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
QAhJn8HC5gmv4AJ5
Listen
